Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma.
Thomas Yau, Jean-François Dufour, René Gérolami, Wattana Sukeepaisarnjaroen, Su Pin Choo, Judit Kocsis, Chia Jui Yen, Yuk Ting Ma, Jean-Frédéric Blanc, Vincenzo Mazzaferro, Paul Ross, Edward J Gane, Karl Heinz Weiss, Philippe Merle, Ho Yeong Lim, Barrett H Childs, Josep M Llovet, Heiko Krissel, Diego Reis, Katrin Roth, Michael Teufel, Satawat Thongsawat, Wisut Lamlertthon, Winnie Yeo, Thong Dao, Markus Peck-Radosavljevic, Baek-Yeol Ryoo
Clinical cancer research : an official journal of the American Association for Cancer Research 2019;24(19):4650-4661